Inventiva S.A. (NASDAQ:IVA) Analyst/Investor Day October 8, 2025 11:30 AM EDT
Company Participants
Mark Pruzanski
Andrew Obenshain – CEO & Director
Jason Campagna – President of Research and Development & Chief Medical Officer
Martine Zimmermann – Executive VP of Regulatory Affairs & Quality Assurance
Conference Call Participants
William Alazawi
Arun Sanyal
Nezam H. Afdhal
Henry E. Chang
Seamus Fernandez – Guggenheim Securities, LLC, Research Division
Yasmeen Rahimi – Piper Sandler & Co., Research Division
Ritu Baral – TD Cowen, Research Division
Edward Nash – Canaccord Genuity Corp., Research Division
Annabel Samimy – Stifel, Nicolaus & Company, Incorporated, Research Division
Ananda Ghosh – H.C. Wainwright & Co, LLC, Research Division
Rami Katkhuda – LifeSci Capital, LLC, Research Division
Antonio Arce – WestPark Capital, Inc., Research Division
Presentation
Mark Pruzanski
Okay. Why don’t we kick things off. Hi, everyone. I’m Mark Pruzanski, I’m the Chairman of the Board of Inventiva and welcome to our investor event. We’re going to be telling you today about the next and hopefully best-in-category oral therapy to get to patients with MASH, lanifibranor. We’re going to be making forward-looking statements. Here’s the agenda.
It’s going to be pretty packed, and I’m going to get out of your way and introduce you to Andrew in a minute followed by 3 well-known, key opinion-leading hepatologists in the MASH space. And then we will a panel discussion with some of the senior management team and time for Q&A at the end. So I’ve been involved with Inventiva for the better part of the year. And it’s been a momentous year. All of you know that we just about a year ago raised a $400-plus million pipe, which positioned the company very well with respect to the enrollment of the global Phase III NATiV3 trial.
We double-clicked to accelerate enrollment and over enrolled the study, which we announced in April of this year. And then
